Publications by authors named "H H Lutz"

The anti-diabetic drug metformin is one of the most widely prescribed medicines in the world. Together with its degradation product guanylurea, it is a major pharmaceutical pollutant in wastewater treatment plants and surface waters. An operon comprising two genes of the ureohydrolase family in Pseudomonas and Aminobacter species has recently been implicated in metformin degradation.

View Article and Find Full Text PDF
Article Synopsis
  • Exosome therapy has potential for heart repair after injury, but challenges like short lifespan and unclear targets limit its clinical use; the study introduces a new method called SCENT (stem cell-derived exosome nebulization therapy) for delivering exosomes through inhalation post-myocardial infarction (MI).
  • Researchers tested SCENT in mice and pigs, finding it improves heart function, reduces tissue scarring, and promotes heart cell growth; advanced imaging techniques helped confirm these benefits.
  • Mechanistic studies indicate that SCENT works by modifying the metabolism in endothelial cells, leading to better heart energy use, as seen in both mouse and pig models, showcasing its potential efficacy and safety for cardiac repair.
View Article and Find Full Text PDF

Disseminated intravascular coagulation (DIC) is a pathologic state that follows systemic injury and other diseases. Often a complication of sepsis or trauma, DIC causes coagulopathy associated with paradoxical thrombosis and hemorrhage. DIC upregulates the thrombotic pathways while simultaneously downregulating the fibrinolytic pathways that cause excessive fibrin deposition, microcirculatory thrombosis, multiorgan dysfunction, and consumptive coagulopathy with excessive bleeding.

View Article and Find Full Text PDF

Oxygen therapeutics have a range of applications in transfusion medicine and disease treatment. Synthetic molecules and all-natural or semi-synthetic hemoglobin-based oxygen carriers (HBOCs) have seen success as potential circulating oxygen carriers. However, many early HBOC products stalled in development due to side effects from excess hemoglobin in the blood stream and hemoglobin entering the tissue.

View Article and Find Full Text PDF

Host cell proteins (HCPs) are process-related impurities in a therapeutic protein expressed using cell culture technology. This review presents biopharmaceutical industry trends in terms of both HCPs in the bioprocessing of monoclonal antibodies (mAbs) and the capabilities for HCP clearance by downstream unit operations. A comprehensive assessment of currently implemented and emerging technologies in the manufacturing processes with extensive references was performed.

View Article and Find Full Text PDF